Evidence map›Paper›PMID 42586424›Full record

ArticleThe Journal of biological chemistry2026

The MHC-I related protein 1 MR1 can bind host purine catabolites.

Mohamed R Abdelaal, Xin Yi Lim, Jeffrey Y W Mak, David P Fairlie, James McCluskey, Alexandra J Corbett, Nicholas A Gherardin, Wael Awad, Jamie Rossjohn

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamed R AbdelaalDepartment of Biochemistry and Molecular Biology, Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia.
Xin Yi LimDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Jeffrey Y W MakCentre for Chemistry and Drug Discovery and ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
David P FairlieCentre for Chemistry and Drug Discovery and ARC Centre of Excellence for Innovations in Peptide and Protein Science, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland, Australia.
James McCluskeyDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Alexandra J CorbettDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Nicholas A GherardinDepartment of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Wael AwadDepartment of Biochemistry and Molecular Biology, Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia.
Jamie RossjohnDepartment of Biochemistry and Molecular Biology, Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Australia. Electronic address: jamie.rossjohn@monash.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The major histocompatibility complex class I-related molecule (MR1) is a non-classical antigen-presenting protein that presents a diverse array of microbial, synthetic and host-generated small metabolites to mucosal-associated invariant T (MAIT) cells and other MR1-restricted T (MR1T) cell populations. Recent studies showed that MR1 binds carbonyl-nucleobase adducts, resulting in the activation of some MR1T cell clones. However, whether endogenous canonical nucleobases and their derivatives can impact the MR1 axis remains unclear. Here, through biochemical and cellular screening of a library of canonical nucleobases and their catabolites, we demonstrate that the catabolites of purine degradation, namely uric acid, xanthine, and xanthosine, can, at high concentrations, bind MR1 and promote its intracellular retention, resulting in reduced MR1 surface expression. These purine-based nucleobases can compete with microbial and non-microbial ligands for MR1 binding. Analysis of three crystal structures of ligand-bound MR1 shows that these endogenous purine-based nucleobases adopt distinct modes of binding and interactions within the MR1 A'-pocket. Accordingly, we broaden the repertoire of MR1-ligandome by describing a group of host xanthine-based compounds that can bind MR1 and regulate its trafficking to the cell surface.

Indexed as

antigen presentationMR1mucosal-associated invariant T cellnucleobasesstructural immunology

Identifiers

PMID42586424
PMCPMC13597202

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.